title: The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.
authors.affiliation: Department of Pathology, Royal Bournemouth Hospital, Dorset, UK.
authors.forename: David M
authors.initials: DM
authors.lastname: Parham
authors.affiliation: Division of Cancer Studies, Kings College London, London, UK.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Pinder
mesh_terms: D000328:Adult; D000368:Aged; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D012189:Retrospective Studies; D000068878:Trastuzumab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human